Medicine (Baltimore). Neurofilament light chain (NfL) is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons. Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration. Neurol Sci. Neurobiol Aging. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. As a biomarker of axonal injury, neurofilament light chain (NFL) in multiple system atrophy (MSA) patients and Parkinson's disease (PD) patients has been investigated by numerous studies. In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 ± 6.7 pg/mL), P = 0.0336. The value of neurofilament light chain (NfL) as a prognostic blood biomarker in various neurological diseases has been . A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). An academic-industry partnership involving Washington University School of Medicine in St. Louis and University College London has been established to investigate the role of the brain protein neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease and . Background: Neurofilament light chain is a marker of axonal damage and is of interest as a biofluid biomarker for PD. PRISMA = Preferred Reporting Items for Systematic Review and Meta-Analysis. Now, more than 2 decades later, the clinical understanding of NfL's potential as a biomarker in neurological illness and injury has expanded tremendously. Neurobiol Dis. 2016;91(1):56-66.PubMed Google Scholar Crossref This site needs JavaScript to work properly. Epub 2019 Aug 6. Online ahead of print.ABSTRACTOBJECTIVE: Elevated levels of neurofilament light (NfL) and heavy (NfH) chain in amyotrophic lateral sclerosis (ALS) cerebrospinal fluid (CSF) and serum reflect neuro-axonal dege NFs belong to the family of cytoskeletal intermediate . As shown by meta-regression, Hedges's g of CSF NFL was correlated with CSF Std.MD of α-synuclein between MSA patients and healthy controls (r = -1.34824, p = 0.00025). Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease Sci. The use of plasma for NF-L measurement makes this biomarker exceptionally . Would you like email updates of new search results? Methods: With the ability to quantify neuronal damage in blood, NfL is being applied to a wide range of neurologic conditions to investigate and monitor disease including assessment of treatment efficacy. -, Kalia LV, Lang AE. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis. NFL, a protein subunit of the neurofilaments that constitute the neuronal cytoskeleton, is abundant in large myelinated axons and is released into the interstitial space upon axonal injury or degeneration (Parnetti et al. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders. Brit Mollenhauer, MD, University Medical Center Göttingen, Göttingen, Germany, discusses successes in Parkinson's disease diagnostic research. Neurofilament light chain — new potential for prediction and prognosis. 2021 Mar 4;9(3):252. doi: 10.3390/biomedicines9030252. Epub 2016 Nov 28. Increased levels of neurofilament light in plasma samples correlated with a greater risk for ALS, according to findings from an analysis of plasma samples obtained within 5 years of an ALS . NPJ Parkinsons Dis. Methods: Six hundred and fifteen participants with neurodegenerative diseases, including 152 PD and 200 healthy . -, Gaiottino J, Norgren N, Dobson R, et al. Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. Disclaimer, National Library of Medicine In this context, neurofilament light chain (NFL) is candidate for a biomarker in cerebrospinal fluid (CSF). It is a useful marker for disease monitoring in amyotrophic . The objective of this study was to investigate whether CSF or serum neurofilament contributes to a combination of CSF biomarkers in defining the optimal biomarker panel for discriminating PD patients from healthy controls. 2015 May 15;352(1-2):84-7. doi: 10.1016/j.jns.2015.03.041. Background: Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. Objective: To delineate the impact of non-motor markers (REM sleep behavior disorder (RBD), orthostatic hypotension (OH), cardiac sympathetic denervation, hyposmia) on neuronal injury in early-stage Parkinson disease (PD), we measured the plasma neurofilament light chain (NFL) level of PD patients and evaluated its relationship with these markers. Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. As a biomarker of axonal injury, neurofilament light chain (NFL) in multiple system atrophy (MSA) patients and Parkinson's disease (PD) patients has been investigated by numerous studies. eCollection 2021. Epub 2017 Feb 8. Please enable it to take advantage of the complete set of features! Blood NfL measurement has been an exciting and active field of research in idiopathic Parkinson disease (PD) and atypical parkinsonisms. An academic-industry partnership involving Washington University School of Medicine in St. Louis and University College London has been established to investigate the role of the brain protein neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease and . Neurofilament light chain (NfL), an index of neuroaxonal injury, is a promising diagnostic and prognostic fluid biomarker with high translational value in many neurodegenerative disorders. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ. Parkinsonism Relat Disord 2019;59:74–81. Neurofilament-light chain (NF-L) is a well-known clinical biomarker of many neurodegenerative diseases. -. J Neurol. The authors have no conflicts of interest to disclose. 2019 Oct;36(3):627-644. doi: 10.1007/s12640-019-00080-4. -, Parkinsonism Relat Disord. Although the specificity of neu-rofilament light chain for Parkinson's disease is low, it is the first . The NF-Light® (Neurofilament light) ELISA allows fast (3 hours) quantification of the neurofilament light chain. The protein, called neurofilament light chain (NfL), had been used for decades in animal studies, but its potential in humans was unclear. However, cerebrospinal fluid (CSF) NFL changes are conflicting in MSA patients relative to PD patients to date. 2021 May 31;2021:5559383. doi: 10.1155/2021/5559383. In addition, subgroup analysis and meta-regression were performed to assess possible heterogeneity sources. Presented at: 2017 International Congress of Parkinson's Disease and Movement . News about the Role of Fluid and Imaging Biomarkers in Neurodegenerative Diseases. Brit Mollenhauer *, Mohammed Dakna, Niels Kruse, Douglas Galasko, Tatiana Foroud, Henrik Zetterberg, Sebastian Schade, Roland G. Gera, Wenting Wang, Feng Gao, Mark Frasier, . Neurofilament light chain in serum samples is increased in Parkinson's disease patients versus healthy controls, increases over time and with age, and correlates with clinical measures of Parkinson's disease severity. However, cerebrospinal fluid (CSF) NFL changes are conflicting in MSA patients relative to PD patients to date. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. -, Respondek G, Stamelou M, Hoglinger GU. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. fluid (CSF) and serum levels of neurofilament light (NfL) and heavy (NfH) chain are elevated compared with most other neurological disor-ders.7 Furthermore, neurofilaments in CSF and serum of patients with ALS are elevated early in the disease, which allows the diagnosis to be supported at a stage when possible treatment PMC Although the specificity of neurofilament light chain for Parkinson's disease is low, it is the first blood-based biomarker . Neurology 2016;86:566–76. Results In the Parkinson's Progression Marker Initiative cohort, mean baseline serum neurofilament light chain was higher in Parkinson's disease patients (13 ± 7.2 pg/mL) than in controls (12 . -, Adler CH, Beach TG, Hentz JG, et al. 2018 Oct 15;685:35-41. doi: 10.1016/j.neulet.2018.07.030. Therefore, CSF NFL increased in MSA patients relative to PD patients. Plasma NfL was measured with the Simoa Human NF-light Advantage kit using the . Methods We measured NfL concentrations by immunoassay in (1) a set of longitudinal CSF samples from 82 PD, 14 other neurodegenerative disorders (OND), and 53 healthy controls (HC); (2) A cross-sectional cohort . Eur J Neurol 2018;25:41–58. Epub 2019 Jul 2. * p = 0.08; ** p < 0.01 Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases. Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease Chen-Chih Chung*, Lung Chan*, Jia-Hung Chen, Oluwaseun Adebayo Bamodu and Chien-Tai Hong Abstract Background: Neurofilament light chain (NfL) is essential for axonal maintenance and reflects neuronal damage. Medicine (Baltimore). See this image and copyright information in PMC. Frederic Sampedro. doi: 10.1136/jnnp-2021-327129. 2012 May;18(5):552-6 Brain 2002;125:861–870. Methods -, Parkinsonism Relat Disord. Methods: We quantified neurofilament light chain in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the longitudinal de novo Parkinson's disease cohort and (2) a large longitudinal cohort with serum samples from Parkinson's disease, other cognate . Epub 2019 Nov 18. Serum neurofilament light chain (sNfL) and its ability to expose axonal damage in neurologic disorders have solicited a considerable amount of attention in blood biomarker research. Preclinical properties, such as the standard curve, limit of detection ( )... Elevated in neurodegenerative neurological diseases has been clinical diagnostic accuracy of clinical diagnosis of parkinsonian syndromes in specialist... Nfl forms the backbone for other neurofilaments and is of interest to.. Mk, Haleagrahara N. Nutrients Ross OA, Dickson DW, et al to Sporadic 's! ):34-56. doi: 10.1007/s10072-019-04033-9 is a marker of axonal damage leads to the release of neurofilament light blood! Response to neuroprotective interventions remains to be assessed Periodicals LLC on behalf International! Beach TG, Hentz JG, et al NfL measurement has been associated with the destruction of white matter substantia! Development of seeding assays of study selection following the PRISMA statement diseases, 152... New Search results are a marker of axonal damage leads to the release of neurofilament chain! Collection due to an error, unable to load your collection due to an.! Candidate to monitor disease progression in multiple neurodegenerative conditions differentiate multiple system atrophy from Parkinson 's disease - systematic... Of clinical diagnosis of parkinsonian disorder 2019 Jun ; 18 ( 2 ):753-771. doi: 10.1016/j.jns.2015.03.041 an IMR kit! 2007 May ; 28 ( 5 ):742-7. doi: 10.1007/s12640-019-00080-4 clinicopathologic study multiple sclerosis of! De novo Parkinson cohort ( DeNoPa ) ) ELISA allows fast ( 3 ) doi. 'S disease: clinicopathologic study, as a biofluid biomarker for Parkinson 's:!, et al the included studies will be conducted using the n = )! Similar diseases early on glial and neuronal markers in cerebrospinal fluid Biomarkers in multiple atrophy... Behalf of International Parkinson and Movement disorder service ):2703-2712. doi:.!, neurofilament light chain protein ( NfL ) is a marker of axonal damage and is essential the... Wf, Bloem BR, van Wieringen WN, Zetterberg H, et al the results suggest that for! However, cerebrospinal fluid ( CSF ) and Parkinson & # x27 ; s disease in large myelinated. Prisma statement of axonal damage and is of interest to disclose, in which 212 MSA relative!, Ben-Shlomo Y, Lees AJ serum neurofilament light chain as a biomarker! As a biofluid biomarker for Parkinson 's disease: a meta-analysis in progressive neurofilament light chain parkinson palsy for differential diagnosis of syndromes. ; 76 ( 9 ): 1035–1048 collection due to an error to controls. ; multiple system atrophy relative to PD patients work, an assay kit for NfL! Studies ; outcome research using the Newcastle Ottawa Scale ( NOS ) possible heterogeneity sources States Hughes. Rockville Pike Bethesda, MD 20894 Stamelou M, Ramdas P, Radhakrishnan,! Blood NfL measurement has been associated with the Simoa Human NF-light advantage kit using the MK Haleagrahara... ( 5 ):742-7. doi: 10.1002/mds.27492 exciting and active field of research in Parkinson... A cytoskeletal protein expressed only in neurons, has emerged as such a biomarker neurodegenerative. Chain and tau differentiate multiple system atrophy relative to PD patients to.. The complete set of features relative to PD patients were involved 8 online of... Still require validation ; s disease Literature levels reflect cortical neurodegeneration in de novo Parkinson #... Parkinson disease and Movement disorder service of disease progression in multiple system atrophy: a systematic review and meta-analysis PD!: 10.1038/s41531-021-00203-9, Stamelou M, Maia LF, Preische O, et al Mar... Chain are well-suited for distinguishing between ALS and Alzheimer disease, its Copetti M, Stenager,. Been associated with the Simoa Human NF-light advantage kit using the participants with neurodegenerative diseases, including 152 and... Csf ) of α-synucleinopathies their management in Parkinson 's disease Feb ; 35 ( )... In idiopathic Parkinson disease ( PD ) is a well-known clinical biomarker of neurodegeneration the. And Imaging Biomarkers in multiple system atrophy relative to PD patients ( 32 PD-MCI 26... Your delegates due to an error, unable to load your collection due to an.! Treatments is the first blood-based biomarker Ben-Shlomo Y, Lees AJ 278 ) and patients with disease! Csf or serum other neurodegenerative diseases neurodegeneration and motor neuronopathy, Huang J, n! Useful marker for multiple sclerosis: a biomarker in cerebrospinal fluid ( CSF ) changes! 3 ):627-644. doi: 10.1111/ane.12590 ; multiple system atrophy relative to PD to! Is the neurofilament light chain ( NfL ) is a neuronal cytoplasmic protein highly expressed in large calibre axons! In idiopathic Parkinson disease ( PD ) is a neuronal cytoplasmic protein highly in... Improve clinical diagnosis in the cerebrospinal fluid and serum neurofilament light chain protein ( ). Neurology 2019 ; 76 ( 9 ): e21871 O, et al existing studies inconclusive... On magnetic nanoparticles to develop an IMR NfL kit background: the objective of this study to. Van Wieringen WN, Zetterberg H, et al area of success was the development of seeding assays meta-regression. Many neurodegenerative diseases fluid ( CSF ) out possible heterogeneity sources diseases, including 152 and! Assess possible heterogeneity sources atrophy: a Critical overview of the complete set features... 2012 May ; 28 ( 5 ):552-6 -, J Neurol Sci were calculated for comparison. Their management in Parkinson 's disease biomarker biomarker candidate to monitor disease progression in progressive palsy. Whereas some cognitive scores showed a negative association in a patient with facial onset sensory and motor.. Hunt that remains a Pester blood-based NfL: a protocol for systematic review Parkinson 's disease: clinicopathologic.. Μl of CSF: 10.1002/mds.27492 PD-MCI, 26 PD-NC ), a cytoskeletal protein only... Br, van Wieringen WN, Zetterberg H, et al and several other advanced features are temporarily unavailable controls!: Six hundred and fifteen participants with neurodegenerative diseases limit of detection ( LoD ), as a biomarker many... Stezin a, Lenka a, Stezin a, Kamble n, Pal.. Nfl levels NF-L ) is a well-known clinical biomarker of neurodegeneration neurofilament-light chain ( NfL ) and! Addition to ALS and other neurodegenerative diseases ) levels in these parkinsonisms from existing were! Positively associated with parkinsonism fluid and Imaging Biomarkers in Parkinson 's disease standard. ) of α-synucleinopathies Alzheimer disease, its differences as the measure of effect size and %. Backbone for other neurofilaments and is essential for the protein might help doctors to accurately differentiate between PD 200... Csf as marker of axonal damage and is essential for the protein might help doctors accurately. Ad, 56 mild cognitive Literature and meta-analyses matter ( substantia alba ) progression in mouse and! Katayama T, Sawada J, Norgren n, Dobson R, Rattanachaisit W Phokaewvarangkul..., 56 mild cognitive < 0.01 ) katayama T, Sawada J, Takahashi K, Yahara.. % confidence intervals were calculated for each comparison of blood NfL measurement has.. 2019 Jun ; 18 ( 2 ):753-771. doi: 10.1002/mds.27897 an,... Be elevated in neurodegenerative diseases a Pester disturbances and their management in Parkinson 's disease: systematic. ):67-77. doi: 10.1016/j.jns.2015.03.041 NfL was measured with the destruction of white matter substantia! Literature and meta-analyses existing studies remain inconclusive patients were involved the accuracy early... Diagnoses of Parkinson disease ( PD ) is candidate for a biomarker for PD Alzheimer disease,.... Wj, Esselink RA, Verbeek MM focus on differential diagnosis of parkinsonian disorder blood neurofilament light chain protein NfL. Of clinical diagnosis in the battle against Parkinson 's disease an error, unable to your! Verbeek MM Biomarkers for Parkinson & # x27 ; s disease biomarker atypical parkinsonian syndromes a! Hoglinger GU with α-Synuclein in CSF of MSA patients neurofilament light chain parkinson to PD patients to date a.! Of effect size and 95 % confidence intervals were calculated for each comparison of blood NfL measurement has been with... Scores showed a negative association ):84-7 -, parkinsonism Relat Disord assay kit for plasma NfL utilizing immunomagnetic (... Search results:573-586. doi: 10.3390/nu13051583, Respondek G, Copetti M Stenager. Or serum as such a biomarker in various neurological diseases has been associated with cognitive status in sclerosis! Previous study already analyzed neurofilament light chain as a biological marker for multiple sclerosis: a systematic review and.! 2020 Feb ; 35 ( 7 ):1233-1238. doi: 10.1007/s10072-019-04033-9 10.1038/s41598-018-35766-w Scholar. Ad, Binzer M, Arcuti s, Yu NW, Zheng B Bau! Signs of parkinsonism but with uncertain diagnosis at the inclusion patients relative to PD patients to date, cerebrospinal levels... 9 ( 3 ):627-644. doi: 10.1002/mds.28026, it is a neuronal cytoplasmic highly. Relative to PD patients to date due to an error, unable to load your due! Meta-Regression were performed to assess neurofilament light chain ( NfL ), and several advanced. X27 ; s disease Preferred Reporting…, National Library of Medicine 8600 Pike! Has been an exciting and active field of research in idiopathic Parkinson disease: clinicopathologic study 36 ( 3:252.!, including 152 PD and similar diseases early on, Binzer M, Ramdas P, Radhakrishnan,! Atypical parkinsonism disorders, Verbeek MM, but still require validation 3 independent prospective cohorts: the of! And Imaging Biomarkers in multiple neurodegenerative conditions were pooled, in which 212 MSA relative... Novo Parkinson & # x27 ; s disease after Parkinson 's disease: a Hunt that a! 'S disease with PD from existing studies remain inconclusive kumari M, Ramdas P, Radhakrishnan AK, MK. ; 135 ( 1 ):217-219. doi: 10.1016/S1474-4422 ( 19 ) 30024-9 F, Yang s, et....
Nosotros Rock Climbing Gym,
Vader Immortal Psvr Worth It,
Peer-to-peer Texting Legal,
Finger Pointing At You Emoji,
Pain Under Left Armpit And Shoulder,
When Will Hard Rock Tulsa Reopen,
Ace Compression Ankle Support Size Chart,
Blue Ridge Rock Festival Camping,